Last reviewed · How we verify
Triomune
At a glance
| Generic name | Triomune |
|---|---|
| Also known as | Stavudine, Lamivudine, Nevirapine |
| Sponsor | Makerere University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) (PHASE2, PHASE3)
- Nevirapine Drug Levels in HIV Positive Patients Also Receiving Rifampicin for Tuberculosis (PHASE4)
- Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients (PHASE4)
- Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+ (PHASE2)
- HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT (PHASE4)
- Triomune Bioequivalence With Innovators (PHASE4)
- Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triomune CI brief — competitive landscape report
- Triomune updates RSS · CI watch RSS
- Makerere University portfolio CI